Singapore: The drug repurposing platform called GRIP (GVK Bio Repurposing Integrated Platform) is a combination of several GVK Bio proprietary and several public domain databases.

It calls for reinvestigating the marketed drugs, clinical and/or pre-clinical candidates and can be applied to many different compounds including those that have failed to show efficacy in late stage clinical trials.

GVK offers a full blown drug repurposing collaborative research services starting from in-silico hypothesis generation to IND enabling studies under one roof.

In addition, GRIP is capable of addressing drug-based, target-based and disease-based repurposing requests and also for generic drugs and innovative compounds (drugs with patent validity, shelved, and pre-clinical stage).

Underlying the Drug Repositioning process is a set of 8 distinct algorithms that allow for unbiased interpretation of the input data to predict alternative indications.
Supplementing GRIP is a team of PhD level scientists and clinicians who help in the accurate interpretation of the data.

GVK Bio and CTCLS have been working together for the past 10 years on marketing and distribution of GVK BIO's GOSTAR, GOBIOM and Clinical Outcomes Databases along with Custom Data Curation Services.

Mr Ryouji Yokoyama, president and CEO, CTCLS, said, "Drug Repositioning has recently grown across the pharmaceutical industry, generating not only clinical development but also business growth. Such trend has been driven by necessity, because the new drug approval rate in Japan has been falling over recent years. Yet the biggest reason for the rising interest in drug repositioning is that it is considered as one of important ways to deliver safer drugs to patients faster and more reliably by discovering new indication from approved drugs and dropout compounds with already confirmed safety and pharmacokinetic properties. In an effort to meet increased demands and challenges, CTCLS has strengthened the sales and marketing of GVK Bio's drug repositioning service by an alliance with GVK Bio. From now on, CTCLS will provide high quality service which can support expanding adaption disease of approved drugs owned by pharmaceutical companies."